Erectile dysfunction (ED) is an increasing disorder [16], affects 25 to 35 million men over 18 years in Europe. Pharmaceuticals used to reduce this disorder act as phosphodiesterase-5 (PDE-5) inhibitors, a family of enzymes typically active in cyclic guanosine monophosphate (cGMP) degradation. The inhibition of PDE-5 results in the intracellular accumulation of cGMP, which plays a central role in signal transduction and regulates several physiological responses.
Parameters/Drugs | Sildenafil (Viagra) | Vardenafil (Levitra) | Tadalafil (Cialis) | Avanafil (Spedra) |
---|---|---|---|---|
Bioavailability | 41% (mean) 25–63% (range) |
15% (mean) | - | - |
Tmax | 1 h (median) 0.5–2 h (range) |
B. calyciflorus | C. dubia | |||||
---|---|---|---|---|---|---|
Sildenafil citrate | 42.74 (34.32–53.21) |
5.74 (3.08–10.71) |
||||
S1 | 19.82 | 1 h (median) 0.5–2 h (range) |
(17.51–22.43) | 6.60 (5.73–7.60) | 2 h (median) 0.5–6 h (range) |
0.5–0.75 h (range) |
Protein binding | 96% | |||||
Tadalafil | NE up to 20 | NE up to 20 | ||||
T1 | NE up to 20 | NE up to 20 |
Compounds | Ames Test | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
TA98 | TA100 | |||||||||
Concentration (μg mL−1) | Mean Revertants/Plate (±SD) | MR a | Concentration (μg mL−1) | Mean Revertants/Plate (±SD) | MR a | |||||
Negative Control2-Nitrofluoren | - | 29.6 ± 2.7 | - | - | ||||||
95% | 94% | 99% | ||||||||
- | Metabolism | Major: CYP3A4 Minor: CYP2C9 |
Major: CYP3A4 Minor: CYP3A5, CYP2C |
CYP3A4 | Major: CYP3A4 Minor: CYP2C |
|||||
190.1 ± 47.2 | - | - | - |
|||||||
2.5 | 61.0 ± 5.7 | 2.1 | ||||||||
5 | 83.2 ± 11.3 | 2.8 | ||||||||
10 | 178.0 ± 15.0 | 6 | Active metabolite(% effect) | Yes (20%) N-demethylation |
Yes (7%) Demethylation |
No | Yes (4%) Methylation, glucuronidation |
|||
Sodium azide | - | - | - | 5 | 488.0 ± 96.9 | 2.6 | Half-life(T1/2) | 4 h | 4–5 h | 17.5 h |
10 | ||||||||||
391.2 ± 69.4 | ||||||||||
13.2 | ||||||||||
10 | ||||||||||
410.7 ± 70.0 | ||||||||||
2.2 | ||||||||||
Species | Test | Pharmaceutical | NOEC or LOEC (µg L−1) |
EC50 (µg L−1) | Classification | ||
---|---|---|---|---|---|---|---|
Asterias rubens | Sperm motility | Sildenafil citrate | NOEC = 0.18 | 60 min = 2.25 × 1012 | Non-toxic | ||
Fertilisation: sperm pre-incubation | Sildenafil citrate | NOEC = 0.010 | 60 min = 7.15 × 1013 | Non-toxic | |||
Fertilisation: oocyte pre-incubation | Sildenafil citrate | NOEC = 0.10 | N/A | N/A | |||
Fertilisation: sperm and oocyte pre-incubation | Sildenafil citrate | NOEC = 0.01 | 60 min = 2.37 × 1012 | Non-toxic | |||
Psammechinus miliaris | Sperm motility | Diclofenac Ibuprofen Sildenafil citrate |
NOEC = 0.01 NOEC = 0.1 NOEC = 0.018 |
60 min = 378.22 60 min = 845.98 60 min = 7.23 × 1010 |
Very toxic Very toxic Non-toxic |
5 h | |
10 | 794.7 ± 90.9 | 4.2 | Elimination | 80% faeces 13% urine |
91–95% faeces 2–6% urine |
61% faeces 36% urine |
62% faeces 21% urine |
Ingestion with high-fat meals | ↓ Cmax 29% ↑ Tmax by 1 h |
↓ Cmax 18–50% | Not affected | ↓ Cmax 24–39% ↑ Tmax by 1.12–1.25 h |
|||
Additional PDE inhibition | PDE1, PDE6 | PDE1, PDE6 | PDE11 | - |
Fertilisation: sperm pre-incubation | ||||||||||
Sildenafil citrate | ||||||||||
NOEC = 0.10 | ||||||||||
60 min = 6.241 × 10 | 10 | Non-toxic | ||||||||
20 | 1153.3 ± 239.8 | 6.1 | ||||||||
Fertilisation: oocyte pre-incubation | Sildenafil citrate | NOEC = 0.01 | N/A | N/A | Sildenafil citrate | 0.625 | 46.7 ± 13.1 | 1.6 | 0.625 | 161.0 ± 18.7 |
Fertilisation: sperm and oocyte pre-incubation | Diclofenac Ibuprofen Sildenafil citrate |
LOEC = 0.01 | 0.8 | |||||||
NOEC = 0.10 | NOEC = 1.0 |
60 min = 247.31 60 min = 792.96 N/A |
Very toxic Very toxic N/A |
1.25 | 48.7 ± 5.1 | 1.6 | 1.25 | |||
Arenicola marina | 164.6 ± 8.7 | 0.9 | ||||||||
Sperm motility | Sildenafil citrate | NOEC = 1.0 | N/A | N/A | 2.5 | 72.0 ± 11.3 | 2.4 | 2.5 | ||
Fertilisation: sperm pre-incubation | Diclofenac Ibuprofen | 190.6 ± 12.6 | Sildenafil citrate | NOEC = 1.00 | 1 | |||||
NOEC = 0.10 | NOEC = 1.0 | 120 min = 565.53 120 min = 3.24 × 109N/A |
Very toxic Non toxic N/A |
5 | 93.0 ± 4.4 | 3.1 | 5 | 198.3 ± 24.0 | ||
Fertilisation: oocyte pre-incubation | 1 | |||||||||
Sildenafil citrate | NOEC = 1.00 | N/A | N/A | 10 | 170.7 ± 32.0 | 5.8 | 10 | 220.0 ± 46.8 | ||
Fertilisation: sperm and oocyte pre-incubation | 1.2 | |||||||||
Sildenafil citrate | NOEC = 1.0 | N/A | N/A | S1 | 0.3125 | 27.8 ± 3.2 | 0.9 | 0.3125 | 241.1 ± 27.5 | 1.3 |
0.625 | 37.6 ± 4.7 | 1.3 | 0.625 | 291.1 ± 21.6 | 1.5 | |||||
1.25 | 37.3 ± 11.6 | 1.3 | 1.25 | 303.1 ± 44.7 | 1.6 | |||||
2.5 | 53.6 ± 9.0 | 1.8 | 2.5 | 376.6 ± 45.3 | 2 | |||||
5 | 64.7 ± 20.2 | 2.2 | 5 | 405.1 ± 82.5 | 2.1 | |||||
10 | 112.4 ± 41.5 | 3.8 | 10 | 444.2 ± 83.2 | 2.3 | |||||
Tadalafil | 0.3125 | 49.5 ± 7.7 | 1.7 | 0.3125 | 298.5 ± 38.7 | 1.6 | ||||
0.625 | 67.2 ± 12.2 | 2.3 | 0.625 | 318.6 ± 65.2 | 1.7 | |||||
1.25 | 149.3 ± 33.2 | 5 | 1.25 | 325.6 ± 94.4 | 1.7 | |||||
2.5 | 223.0 ± 54.8 | 7.5 | 2.5 | 425.3 ± 80.9 | 2.2 | |||||
5 | 337.3 ± 32.3 | 11.4 | 5 | 556.0 ± 41.7 | 2.9 | |||||
10 | 544.0 ± 92.1 | 18.4 | 10 | 880.0 ± 237.6 | 4.6 | |||||
T1 | 0.625 | 43.6 ± 11.9 | 1.5 | 0.625 | 286.0 ± 14.1 | 1.5 | ||||
1.25 | 43.5 ± 14.0 | 1.5 | 1.25 | 310.7 ± 43.9 | 1.6 | |||||
2.5 | 85.4 ± 19.2 | 2.9 | 2.5 | 322.7 ± 28.4 | 1.7 | |||||
5 | 221.8 ± 57.2 | 7.5 | 5 | 288.0 ± 40.6 | 1.5 |